M-M-R II

Live MMR virus vaccine

Simultaneous vaccination against MMR in individuals ≥12 mth.

SC 0.5 mL into the outer aspect of upper arm. Recommended vaccination schedule Individuals 1st vaccinated at ≥12 mth should be revaccinated at 4-6 yr. Measles outbreak schedule Infant 6-12 mth Administer 2nd dose at 12-15 mth followed by revaccination at 4-6 yr. Use w/ other vaccines Administer one mth before or after administration of other live viral vaccines.

Hypersensitivity to components including gelatin; anaphylactic/anaphylactoid reactions to neomycin. Febrile resp illness or other active febrile infection. Active untreated TB. Patients receiving immunosuppressive therapy except those receiving corticosteroids as replacement therapy (eg, for Addison's disease). Blood dyscrasias, leukemia, lymphomas or other malignant neoplasms affecting bone marrow or lymphatic systems. Primary & acquired immunodeficiency states including immunosuppressed patients associated w/ AIDS or other clinical manifestations of HIV infection, cellular immune deficiencies, hypogammaglobulinemic & dysgammaglobulinemic states. Family history of congenital/hereditary immunodeficiency. Pregnancy.

Adequate treatment provisions including epinephrine inj should be available for immediate use if anaphylactic/anaphylactoid reaction occur. History of anaphylactic, anaphylactoid or other immediate reactions (eg, hives, swelling of mouth & throat, difficulty breathing, hypotension, shock) subsequent to egg ingestion. Do not inj intravascularly. Individual or family history of convulsions, cerebral injury or other condition in which stress due to fever should be avoided. Individuals w/ current thrombocytopenia may develop more severe thrombocytopenia following vaccination. Individuals who experienced thrombocytopenia w/ 1st dose of M-M-R II (or its component vaccines) may develop thrombocytopenia w/ repeat doses. Closely monitor HIV-infected vaccinees for vaccine-preventable diseases. Possible measles inclusion body encephalitis, pneumonitis & death in severely immunocompromised individuals inadvertently vaccinated w/ measles-containing vaccine. May result in temporary tuberculin skin sensitivity depression. Administer tuberculin test either before, simultaneously w/, or at least 4-6 wk after M-M-R II. May not protect 100% of vaccinees. Do not give Ig concurrently. Individuals planning to travel abroad (if not immune) can acquire MMR. Vaccination has been recommended for susceptible individuals in high-risk groups (eg, college students, healthcare workers & military personnel). Vaccination of individuals exposed to wild-type measles may provide some protection if vaccinated w/in 72 hr of exposure. Immunization of susceptible non-pregnant adolescent & adult females of childbearing age. Advise women of childbearing age not to become pregnant for 1 mth after vaccination. Inform postpubertal females of frequent occurrence of generally self-limited arthralgia &/or arthritis beginning 2-4 wk after vaccination. Previously unvaccinated childn >12 mth who are in contact w/ susceptible pregnant woman should receive live attenuated rubella vaccine to reduce risk of exposure of the pregnant woman. Lactation. Childn under treatment for TB who have not experienced disease exacerbation when immunized w/ live measles virus vaccine; untreated tuberculous childn. Infant <6 mth (measles) & <12 mth (mumps & rubella).

Burning &/or stinging of short duration at inj site. Fever; usually minimal but may be generalized or measles-like rash.

Concurrent administration w/ Ig may interfere w/ expected immune response; defer vaccination for ≥3 mth following administration of Ig (human) & blood/plasma transfusions.

Vaccines, Antisera & Immunologicals

J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.

POM